Rocapuldencel-T
drug drugOn this page
Also known as Ags-003AGS-003 MDCSArcelis
Summary
Rocapuldencel-T (CHEMBL3545128) is a phase-3 clinical-stage cell; indicated across 2 conditions including renal cell carcinoma and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Cell
- Indications: 2 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545128 |
| Name | Rocapuldencel-T |
| Type | Cell |
| Max phase | 3 |
Also known as: Ags-003, AGS-003, AGS-003 MDCS, Arcelis, Rocapuldencel-t, ROCAPULDENCEL-T
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| renal cell carcinoma | 3 | MONDO:0005086 | EFO:0000681 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01582672 | PHASE3 | TERMINATED | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma |
| NCT00272649 | PHASE1/PHASE2 | COMPLETED | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer |
| NCT00678119 | PHASE2 | COMPLETED | Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment |
| NCT01482949 | PHASE2 | TERMINATED | A Rollover Protocol for Subjects Previously Treated With AGS-003 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: renal cell carcinoma, non-small cell lung carcinoma